Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT ID: NCT06422143
Last Updated: 2026-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
851 participants
INTERVENTIONAL
2024-06-10
2031-02-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
NCT02775435
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788
Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC
NCT06706219
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
NCT03976362
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Maintenance Arm A: Pembrolizumab + sac-TMT
During the Induction phase, participants receive pembrolizumab 200 mg q3w for 4 cycles, carboplatin area under the curve (AUC) 6 (mg/mL/min) q3w for 4 cycles, and paclitaxel 200 mg/m2 q3w for 4 cycles or nab-paclitaxel 100 mg/m2 weekly for 4 cycles. Note: per investigator discretion, carboplatin AUC 5 mg/mL/min q3w or paclitaxel 175mg/m2 q3w may be administered.
During the Maintenance phase, participants receive sac-TMT 4 mg/kg infusion every 2 weeks (q2w) until discontinuation criteria is met for sac-TMT; and pembrolizumab 400 mg every 6 weeks (q6w) for 96 weeks.
Pembrolizumab
Intravenous (IV) infusion
sac-TMT
IV infusion
Carboplatin
Participants receive AUC 6 or AUC 5 mg/mL/min IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
Paclitaxel
Participants receive 200 mg/m\^2 or 175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
Nab-paclitaxel
Participants receive 100 mg/m\^2 IV infusion on Days 1, 8 and 15 of each 21-day cycle for 4 cycles as background therapy during the study.
Maintenance Arm B: Pembrolizumab Monotherapy
During the Induction phase, participants receive pembrolizumab 200 mg q3w for 4 cycles, carboplatin AUC 6 (mg/mL/min) q3w for 4 cycles, and paclitaxel 200 mg/m2 q3w for 4 cycles or nab-paclitaxel 100 mg/m2 weekly for 4 cycles.
During the Maintenance phase, participants receive pembrolizumab 400 mg q6w for 96 weeks.
Pembrolizumab
Intravenous (IV) infusion
Carboplatin
Participants receive AUC 6 or AUC 5 mg/mL/min IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
Paclitaxel
Participants receive 200 mg/m\^2 or 175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
Nab-paclitaxel
Participants receive 100 mg/m\^2 IV infusion on Days 1, 8 and 15 of each 21-day cycle for 4 cycles as background therapy during the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pembrolizumab
Intravenous (IV) infusion
sac-TMT
IV infusion
Carboplatin
Participants receive AUC 6 or AUC 5 mg/mL/min IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
Paclitaxel
Participants receive 200 mg/m\^2 or 175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
Nab-paclitaxel
Participants receive 100 mg/m\^2 IV infusion on Days 1, 8 and 15 of each 21-day cycle for 4 cycles as background therapy during the study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the local site investigator/radiology
* Has life expectancy ≥3 months
* Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 assessed within 7 days prior to allocation
* Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
* Participants who are hepatitis B surface antigen (HBsAg)-positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation
* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible)
* Has adequate organ function
* For Maintenance only (prior to randomization): is without disease progression of their NSCLC, as determined by BICR using RECIST 1.1 after completion of study-specified Induction with an evaluable scan at Week 12 or most recent scan before randomization
* For Maintenance only (prior to randomization): has ECOG PS of 0 or 1 as assessed at the Prerandomization Visit
* For Maintenance only (prior to randomization): all AEs (with the exception of alopecia, Grade ≤2 fatigue, Grade ≤2 peripheral neuropathy, and Grade ≤2 endocrine-related AEs requiring treatment or hormone replacement) have recovered
Exclusion Criteria
* History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)
* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \>480 ms, and other serious cardiovascular and cerebrovascular diseases within 6 months before study intervention
* HIV-infected participants who have been newly diagnosed or with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as a part of neoadjuvant or adjuvant therapy or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC
* Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti programmed cell death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T lymphocyte-associated protein 4, OX-40, CD137). Note: Prior treatment with an anti-PD-1 or anti-PD-L1 agent for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC
* Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antidrug conjugate (ADC)
* Received radiation therapy to the lung that is \>30 Gray within 6 months of start of study intervention
* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
* Participants who have not adequately recovered from major surgery or have ongoing surgical complications
* Received prior treatment with a topoisomerase I inhibitor-containing ADC
* Is currently receiving a strong inducer/inhibitor of CYP3A4 that cannot be discontinued for the duration of the study (the required washout period before starting sac-TMT is 2 weeks)
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Has known central nervous system (CNS) metastases/carcinomatous meningitis
* Severe hypersensitivity (≥Grade 3) to study intervention and/or any of its excipients or to another biologic therapy
* Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapy \[eg, thyroxine, insulin, or physiologic corticosteroid\] is allowed)
* History of (noninfectious)pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Active infection requiring systemic therapy
* History of allogeneic tissue/solid organ transplant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CARTI Cancer Center ( Site 0006)
Little Rock, Arkansas, United States
Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0122)
Burbank, California, United States
Exempla Lutheran Medical Center ( Site 0119)
Golden, Colorado, United States
Intermountain Health St. Mary's Regional Hospital ( Site 0116)
Grand Junction, Colorado, United States
Mid Florida Hematology and Oncology Center ( Site 0109)
Orange City, Florida, United States
Centricity Research Columbus Cancer Center ( Site 0111)
Columbus, Georgia, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0001)
Marietta, Georgia, United States
Southeastern Regional Medical Center ( Site 0004)
Newnan, Georgia, United States
University of Chicago Medical Center ( Site 0145)
Chicago, Illinois, United States
Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0146)
Minneapolis, Minnesota, United States
New Mexico Oncology Hematology Consultants Ltd. ( Site 0123)
Albuquerque, New Mexico, United States
University of New Mexico Comprehensive Cancer Center ( Site 0135)
Albuquerque, New Mexico, United States
St Luke's University Health Network ( Site 0017)
Bethlehem, Pennsylvania, United States
Thomas Jefferson University - Clinical Research Institute ( Site 0147)
Philadelphia, Pennsylvania, United States
Memorial Hermann Cancer Center ( Site 0015)
Houston, Texas, United States
Oncology Consultants P.A. ( Site 0124)
Houston, Texas, United States
Mays Cancer Center ( Site 0132)
San Antonio, Texas, United States
Instituto Alexander Fleming ( Site 0203)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0200)
Mar del Plata, Buenos Aires, Argentina
Instituto Médico Río Cuarto ( Site 0204)
Río Cuarto, Córdoba Province, Argentina
Fundacion Intecnus ( Site 0205)
Bariloche, Río Negro Province, Argentina
Sanatorio Parque ( Site 0201)
Rosario, Santa Fe Province, Argentina
Hospital Aleman-Oncology ( Site 0202)
Buenos Aires, , Argentina
Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0720)
Linz, Upper Austria, Austria
Klinik Hietzing ( Site 0740)
Vienna, , Austria
Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 0730)
Vienna, , Austria
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0710)
Vienna, , Austria
Hospital do Cancer de Pernambuco ( Site 0312)
Recife, Pernambuco, Brazil
Vencer Centro de Pesquisa Clínica ( Site 0309)
Teresina, Piauí, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0311)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceição ( Site 0300)
Porto Alegre, Rio Grande do Sul, Brazil
Instituto de Oncologia Saint Gallen ( Site 0304)
Santa Cruz do Sul, Rio Grande do Sul, Brazil
Hospital de Base de São José do Rio Preto ( Site 0310)
São José do Rio Preto, São Paulo, Brazil
Hospital Paulistano ( Site 0307)
São Paulo, , Brazil
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0100)
Kingston, Ontario, Canada
Waterloo Regional Health Network (WRHN) ( Site 0153)
Kitchener, Ontario, Canada
St. Marys Hospital Center ( Site 0105)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 0103)
Montreal, Quebec, Canada
Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0106)
Trois-Rivières, Quebec, Canada
Centro de Investigación del Maule ( Site 0419)
Talca, Maule Region, Chile
FALP ( Site 0409)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0402)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 0407)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 0400)
Viña del Mar, Región de Valparaíso, Chile
Bradford Hill Norte ( Site 0420)
Antofagasta, , Chile
Beijing Cancer Hospital ( Site 2411)
Beijing, Beijing Municipality, China
Beijing Cancer hospital-intrathoratic deparmtment II ( Site 2410)
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital ( Site 2412)
Beijing, Beijing Municipality, China
Army Medical Center of People's Liberation Army-respiratory ( Site 2426)
Chongqing, Chongqing Municipality, China
Fujian Provincial Cancer Hospital ( Site 2419)
Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University-oncology ( Site 2420)
Xiamen, Fujian, China
The First Affiliated Hospital of Guangzhou Medical University ( Site 2417)
Guangzhou, Guangdong, China
Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 2416)
Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital-oncology of department ( Site 2415)
Harbin, Heilongjiang, China
Henan Cancer Hospital-Pneumology department ( Site 2423)
Zhengzhou, Henan, China
Tongji Hospital Tongji Medical,Science & Technology ( Site 2424)
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University-Oncology ( Site 2418)
Changsha, Hunan, China
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 2402)
Huai'an, Jiangsu, China
Northern Jiangsu People's Hospital-General Surgery Department ( Site 2403)
Yangzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 2405)
Nanchang, Jiangxi, China
The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 2404)
Nanchang, Jiangxi, China
Jilin Province Tumor Hospital-GCP office ( Site 2413)
Changchun, Jilin, China
The First Hospital of Jilin University-Oncology ( Site 2414)
Changchun, Jilin, China
Shanghai East Hospital ( Site 2428)
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital ( Site 2427)
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University ( Site 2422)
Chengdu, Sichuan, China
Sichuan Cancer hospital. ( Site 2421)
Chengdu, Sichuan, China
The Affiliated Cancer Hospital of Xinjiang Medical University ( Site 2425)
Ürümqi, Xinjiang, China
The first Affiliated Hospital, Zhejiang University School of Medicine-Respiratory Department ( Site 2406)
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Medical Oncology ( Site 2407)
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital-Breast Oncology ( Site 2408)
Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province ( Site 2430)
Taizhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University-Respiratory department ( Site 2409)
Wenzhou, Zhejiang, China
Centro Cancerológico del Caribe (CECAC) ( Site 0509)
Barranquilla, Atlántico, Colombia
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0500)
Bogotá, Bogota D.C., Colombia
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0501)
Valledupar, Cesar Department, Colombia
Oncologos del Occidente ( Site 0504)
Pereira, Risaralda Department, Colombia
Fundación Valle del Lili-Oncology CIC ( Site 0505)
Cali, Valle del Cauca Department, Colombia
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0800)
Brno, Brno-mesto, Czechia
Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni oddeleni ( Site 0803)
Ostrava-Vitkovice, Ostrava Mesto, Czechia
Multiscan-Onkologicke a radiologicke centrum Multiscan Pardubice ( Site 0804)
Pardubice, Pardubický kraj, Czechia
Fakultni nemocnice Olomouc-Klinika plicnich nemoci a tuberkulozy ( Site 0802)
Olomouc, , Czechia
Clinique Clairval ( Site 0904)
Marseille, Bouches-du-Rhone, France
Hôpital Robert Schuman ( Site 0907)
Vantoux, Lorraine, France
Institut de Cancérologie de l'Ouest ( Site 0908)
Angers, Maine-et-Loire, France
Sainte Catherine Institut du Cancer Avignon Provence ( Site 0902)
Avignon, Vaucluse, France
CHD Vendee ( Site 0901)
La Roche-sur-Yon, Vendee, France
Hôpital Saint-Louis ( Site 0906)
Paris, , France
GEFOS Gesellschaft f. onkologische Studien ( Site 1005)
Dortmund, North Rhine-Westphalia, Germany
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung ( Site 1001)
Essen, North Rhine-Westphalia, Germany
Universitätsklinikum Schleswig-Holstein-Pneumologie ( Site 1000)
Lübeck, Schleswig-Holstein, Germany
SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 1006)
Gera, Thuringia, Germany
Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 1003)
Berlin, , Germany
Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 1100)
Kecskemét, Bács-Kiskun county, Hungary
Petz Aladar Egyetemi Oktato Korhaz ( Site 1101)
Győr, Győr-Moson-Sopron, Hungary
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 1103)
Szolnok, Jász-Nagykun-Szolnok, Hungary
Reformatus Pulmonologiai Centrum ( Site 1102)
Törökbálint, Pest County, Hungary
Zala Megyei Szent Rafael Kórház ( Site 1110)
Zalaegerszeg, Zala County, Hungary
Országos Korányi Pulmonológiai Intézet ( Site 1104)
Budapest, , Hungary
St. James's Hospital ( Site 1200)
Dublin, , Ireland
Rambam Health Care Campus-Oncology Division ( Site 1302)
Haifa, , Israel
Shaare Zedek Medical Center ( Site 1300)
Jerusalem, , Israel
Rabin Medical Center ( Site 1303)
Petah Tikva, , Israel
Sheba Medical Center ( Site 1301)
Ramat Gan, , Israel
Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia clinica sperimentale Toraco-Polmonare ( Site 1401)
Napoli, Campania, Italy
Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 1409)
Rome, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1404)
Milan, Lombardy, Italy
Fondazione IRCCS San Gerardo dei Tintori-Oncologia ( Site 1412)
Monza, Lombardy, Italy
Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1408)
Rozzano, Milano, Italy
Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1402)
Rome, Roma, Italy
Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 1414)
Brescia, , Italy
Ospedale San Martino ( Site 1407)
Genova, , Italy
Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 1410)
Pavia, , Italy
Ospedale di Circolo e Fondazione Macchi Varese-Oncology ( Site 1413)
Varese, , Italy
Centro Ricerche Cliniche di Verona s.r.l. c/o Policlinico G.B.Rossi ( Site 1415)
Verona, , Italy
Aichi Cancer Center ( Site 2502)
Nagoya, Aichi-ken, Japan
Nagoya University Hospital ( Site 2519)
Nagoya, Aichi-ken, Japan
Fujita Health University Hospital ( Site 2515)
Toyoake, Aichi-ken, Japan
Hirosaki University Hospital ( Site 2514)
Hirosaki, Aomori, Japan
National Cancer Center Hospital East ( Site 2501)
Kashiwa, Chiba, Japan
Ehime University Hospital ( Site 2511)
Tōon, Ehime, Japan
Gunma Prefectural Cancer Center ( Site 2510)
Ōta, Gunma, Japan
Takarazuka City Hospital ( Site 2508)
Takarazuka, Hyōgo, Japan
Kanazawa University Hospital ( Site 2513)
Kanazawa, Ishikawa-ken, Japan
St. Marianna University Hospital ( Site 2521)
Kawasaki, Kanagawa, Japan
Kanagawa Cardiovascular and Respiratory Center ( Site 2518)
Yokohama, Kanagawa, Japan
Kanagawa Cancer Center ( Site 2504)
Yokohama, Kanagawa, Japan
Matsusaka Municipal Hospital ( Site 2522)
Matsusaka, Mie-ken, Japan
Sendai Kousei Hospital ( Site 2507)
Sendai, Miyagi, Japan
Kansai Medical University Hospital ( Site 2503)
Hirakata, Osaka, Japan
National Hospital Organization Ureshino Medical Center ( Site 2524)
Ureshino, Saga-ken, Japan
Saitama Prefectural Cancer Center ( Site 2512)
Kitaadachi-gun, Saitama, Japan
Cancer Institute Hospital of JFCR ( Site 2500)
Koto, Tokyo, Japan
Toho University Omori Medical Center ( Site 2520)
Ōta-ku, Tokyo, Japan
National Center for Global Health and Medicine ( Site 2516)
Shinjuku, Tokyo, Japan
National Hospital Organization Yamaguchi Ube Medical Center ( Site 2523)
Ube, Yamaguchi, Japan
Chiba University Hospital ( Site 2517)
Chiba, , Japan
National Hospital Organization Kyushu Medical Center ( Site 2509)
Fukuoka, , Japan
Niigata Cancer Center Hospital ( Site 2505)
Niigata, , Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 2506)
Osaka, , Japan
Clínica San Antonio ( Site 0606)
Trujillo, La Libertad, Peru
Clínicas AUNA Sede Chiclayo ( Site 0604)
Chiclayo, Lambayeque, Peru
Oncosalud-Clinical Research ( Site 0600)
Lima, , Peru
Hospital Militar Central Coronel Luis Arias Schereiber ( Site 0602)
Lima, , Peru
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1503)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Regionalny Szpital Specjalistyczny im. dr. Władyslawa Biegańskiego ( Site 1513)
Grudziądz, Kuyavian-Pomeranian Voivodeship, Poland
Szpital Specjalistyczny im. Henryka Klimontowicza ( Site 1507)
Gorlice, Lesser Poland Voivodeship, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie-Oncology Department ( Site 1515)
Krakow, Lesser Poland Voivodeship, Poland
Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 1510)
Poznań, Lower Silesian Voivodeship, Poland
Instytut Gruźlicy i Chorób Płuc w Warszawie ( Site 1523)
Warsaw, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 1500)
Warsaw, Masovian Voivodeship, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1501)
Przemyśl, Podkarpackie Voivodeship, Poland
Szpital Wojewódzki w Koszalinie. ( Site 1517)
Poland, West Pomeranian Voivodeship, Poland
Centrul Medical Medicover Victoria ( Site 2000)
Bucharest, București, Romania
Cardiomed SRL Cluj-Napoca ( Site 2002)
Cluj-Napoca, Cluj, Romania
SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 2001)
Florești, Cluj, Romania
Centrul de Oncologie Sfantul Nectarie-Medical ( Site 2004)
Craiova, Dolj, Romania
Cabinet Medical Oncomed ( Site 2005)
Timișoara, Timiș County, Romania
SC ONCO CARD SRL ( Site 2007)
Brasov, , Romania
Lotus-Med ( Site 2009)
Bucharest, , Romania
Clinica Polisano ( Site 2008)
Sibiu, , Romania
The Catholic University of Korea, Incheon St. Mary's Hospital ( Site 2106)
Bupyeong-gu, Incheon, South Korea
Pusan National University Yangsan Hospital ( Site 2104)
Yangsan, Kyongsangnam-do, South Korea
Pusan National University Hospital ( Site 2100)
Busan, Pusan-Kwangyokshi, South Korea
Kyungpook National University Chilgok Hospital-Pulmonology ( Site 2102)
Deagu, Taegu-Kwangyokshi, South Korea
Chungnam national university hospital-Department of Internal Medicine ( Site 2107)
Daejeon, Taejon-Kwangyokshi, South Korea
Kyung Hee University Hospital ( Site 2101)
Seoul, , South Korea
Asan Medical Center ( Site 2105)
Seoul, , South Korea
Korea University Guro Hospital-Internal Medicine ( Site 2103)
Seoul, , South Korea
CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 1703)
Santiago de Compostela, Galicia, Spain
Hospital Insular de Gran Canaria-Oncology ( Site 1701)
Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Quirón Málaga ( Site 1704)
Málaga, Malaga, Spain
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1700)
Barcelona, , Spain
Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 1702)
Madrid, , Spain
Hospital Universitario Virgen de Valme-Departamento de Oncologia ( Site 1705)
Seville, , Spain
National Taiwan University Cancer Center (NTUCC) ( Site 2209)
Taipei City, Taipei, Taiwan
Taoyuan General Hospital ( Site 2203)
Taoyuan, Taoyuan, Taiwan
Chang Gung Memorial Hospital at Kaohsiung ( Site 2207)
Kaohsiung City, , Taiwan
Taichung Veterans General Hospital ( Site 2204)
Taichung, , Taiwan
National Cheng Kung University Hospital ( Site 2205)
Tainan, , Taiwan
National Taiwan University Hospital-Oncology ( Site 2208)
Taipei, , Taiwan
Mackay Memorial Hospital-Chest Medicine ( Site 2201)
Taipei, , Taiwan
Chang Gung Medical Foundation-Linkou Branch-Clinic of Chest Medicine ( Site 2202)
Taoyuan District, , Taiwan
Faculty of Medicine Siriraj Hospital ( Site 2301)
Bangkok, Bangkok, Thailand
Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 2300)
Dusit, Bangkok, Thailand
Prapokklao Hospital ( Site 2306)
Mueang, Changwat Chanthaburi, Thailand
Faculty of Medicine - Khon Kaen University ( Site 2305)
Muang, Changwat Khon Kaen, Thailand
Lampang Cancer Hospital ( Site 2304)
Lampang, Changwat Lampang, Thailand
Songklanagarind hospital ( Site 2303)
Hat Yai, Changwat Songkhla, Thailand
Maharaj Nakorn Chiang Mai Hospital ( Site 2302)
Chiang Mai, , Thailand
Medipol Mega Universite Hastanesi-oncology ( Site 1811)
Stanbul, Istanbul, Turkey (Türkiye)
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1801)
Ankara, , Turkey (Türkiye)
Gazi Universitesi-Oncology ( Site 1804)
Ankara, , Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1800)
Ankara, , Turkey (Türkiye)
Izmir Atatürk Training and Research Hospital ( Site 1810)
Izmir, , Turkey (Türkiye)
Memorial Kayseri Hastanesi ( Site 1805)
Kayseri, , Turkey (Türkiye)
Mersin Sehir Eğitim ve Araştırma Hastanesi-Oncology ( Site 1808)
Mersin, , Turkey (Türkiye)
Samsun Medical Park Hastanesi-medical oncology ( Site 1806)
Samsun, , Turkey (Türkiye)
Cleveland Clinic Abu Dhabi ( Site 2650)
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
Burjeel Medical City ( Site 2600)
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
North West Cancer Centre ( Site 1908)
Londonderry, Derry and Strabane, United Kingdom
Torbay Hospital ( Site 1906)
Torquay, Devon, United Kingdom
St Bartholomew's Hospital ( Site 1901)
London, London, City of, United Kingdom
City Hospital, Nottingham University Hospitals NHS Trust-NCCTT ( Site 1911)
Nottingham, Nottinghamshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-510128-66-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1301-2790
Identifier Type: REGISTRY
Identifier Source: secondary_id
jRCT2021240015
Identifier Type: REGISTRY
Identifier Source: secondary_id
MK-2870-023
Identifier Type: OTHER
Identifier Source: secondary_id
2870-023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.